The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
 
Jesse Zaretsky
No Relationships to Disclose
 
Riley Mullins
No Relationships to Disclose
 
Thomas Barrett
No Relationships to Disclose
 
Peter Oppelt
Research Funding - Enzychem Lifesciences (Inst); HiFiBiO Therapeutics (Inst); Merck (Inst)
 
Jessica Ley
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Emily Stoller
No Relationships to Disclose
 
Porter Bischoff
No Relationships to Disclose
 
Ryan Jackson
Honoraria - Intuitive Surgical
 
Patrik Pipkorn
No Relationships to Disclose
 
Richard Harbison
No Relationships to Disclose
 
Wade Thorstad
No Relationships to Disclose
 
Nikhil Rammohan
No Relationships to Disclose
 
Jennifer De Los Santos
No Relationships to Disclose
 
Michael Moravan
Honoraria - RTI Health Solutions (I)
Consulting or Advisory Role - Microaire (I)
 
Anthony Apicelli
No Relationships to Disclose
 
Steven Quayle
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Patents, Royalties, Other Intellectual Property - Acetylon Pharmaceuticals
 
Matteo Levisetti
Employment - Cue Biopharma
Leadership - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
 
Anish Suri
Employment - Cue Biopharma
Leadership - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Patents, Royalties, Other Intellectual Property - Cue Biopharma
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Sidharth Puram
No Relationships to Disclose